Becton, Dickinson and Company (BDX) Expected to Post Quarterly Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) is anticipated to release its Q4 2026 results before the market opens on Thursday, November 5th. Analysts expect Becton, Dickinson and Company to announce earnings of $4.07 per share and revenue of $5.11 billion for the quarter. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Investors can check the company’s upcoming Q4 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the business earned $3.68 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% on a year-over-year basis. On average, analysts expect Becton, Dickinson and Company to post $12.67 EPS for the current fiscal year and $13.24 EPS for the next fiscal year.

Becton, Dickinson and Company Trading Up 0.4%

Shares of BDX stock opened at $198.77 on Tuesday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $200.47. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The stock’s 50-day moving average price is $186.71 and its 200-day moving average price is $170.25. The stock has a market capitalization of $54.77 billion, a price-to-earnings ratio of 59.87, a price-to-earnings-growth ratio of 13.16 and a beta of 0.21.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 6,907 shares of company stock worth $1,269,128. Company insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on BDX shares. Bank of America raised their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Monday, August 31st. Piper Sandler lifted their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Zacks Research upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. Finally, Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $185.07.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.